Advancements in tumor immunology have resulted in the identification of TAAs that can be used for cancer vaccines, in which the TAA-derived epitopes are combined with HLA class I molecules, followed by recognition by CD8+ cytotoxic T lymphocytes (CTLs). This evidence concerns the gene CD8A and neoplasm.